Originally published by our sister publication Specialty Pharmacy Continuum
By SPC Staff
The FDA approved benralizumab (Fasenra, AstraZeneca) for adults with eosinophilic granulomatosis with polyangiitis (EGPA).
The disease causes immune-mediated vasculitis that can damage multiple organs and be fatal without treatment. Benralizumab is a monoclonal antibody that inhibits the interleukin-5alpha receptor expressed on eosinophils and is given as a monthly subcutaneous injection; it has previously